Discover

ALT
Altimmune, Inc.
3.15
2 x 2.44
2 x 3.89
bid
ask
+
0.11
3.62%
2 @ 07:12 AM
3.20 +0.05 (1.59%)
Ytd-12.74%
1y-25.53%
3.00
day range
3.40
2.56
52 week range
6.44
Open3.02Prev Close3.04Low3.00High3.40Mkt Cap612.59M
Vol7.96MAvg Vol4.21MEPS-0.92P/EN/AForward P/E-5.14
Beta0.07Short Ratio5.81Inst. Own56.68%DividendN/ADiv YieldN/A
Ex Div Date01-20Earning08-1150-d Avg2.89200-d Avg3.861yr Est22.86

ALT News

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
gurufocus.com
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Ado

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
zacks.com
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art

5 Small Drug Stocks to Invest in Amid a Biotech Comeback
zacks.com
5 Small Drug Stocks to Invest in Amid a Biotech Comeback

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr

benzinga.com
Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $

Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperf

benzinga.com
Altimmune Announces New Data From Phase 2b Trial Of Pemvidutide Showing Improvements Across Multiple

The data are being presented today and Friday in poster sessions, including a late-breaking poster p

benzinga.com
HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

benzinga.com
Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11

Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and

Altimmune Q1 2026 Earnings Call: Complete Transcript
benzinga.com
Altimmune Q1 2026 Earnings Call: Complete Transcript

benzinga.com
Altimmune To Present Analyses Of Data From IMPACT Phase 2b Clinical Trial In Metabolic Dysfunction-A

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in "

benzinga.com
Altimmune Q1 EPS $(0.18) Beats $(0.25) Estimate.

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.18) per share which beat the analyst consens

Earnings Scheduled For May 13, 2026
benzinga.com
Earnings Scheduled For May 13, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

Why Is Altimmune Stock Falling Today?
benzinga.com
Why Is Altimmune Stock Falling Today?

Altimmune shares fall after a $225 million offering raises dilution concerns while funding key late-

ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
benzinga.com
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thurs

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
benzinga.com
ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thurs

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com
Altimmune Announces Public Offering; Quantity And Termination Date Not Disclosed

Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 t

benzinga.com
HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy a

benzinga.com
B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13

B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers

Altimmune: Q4 Earnings Insights
benzinga.com
Altimmune: Q4 Earnings Insights

benzinga.com
Altimmune Q4 EPS $(0.27) Up From $(0.33) YoY, Sales $26.000K Up From $5.000K YoY

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent incre

Earnings Scheduled For March 5, 2026
benzinga.com
Earnings Scheduled For March 5, 2026

What to Expect from Altimmune's Earnings
benzinga.com
What to Expect from Altimmune's Earnings

Altimmune (ALT) Shares Slide On $75 Million Stock Offering
benzinga.com
Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million

Qorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
Qorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Marke

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why F5 Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why F5 Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

Booz Allen Posts Upbeat Q3 Earnings, Joins Life360, Redwire And Other Big Stocks Moving Higher On Friday
benzinga.com
Booz Allen Posts Upbeat Q3 Earnings, Joins Life360, Redwire And Other Big Stocks Moving Higher On Fr

Why Are Investors Looking At Altimmune Stock?
benzinga.com
Why Are Investors Looking At Altimmune Stock?

Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy

Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday
benzinga.com
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday

benzinga.com
Market-Moving News for January 5th

ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designatio

benzinga.com
Altimmune Says FDA Grants Breakthrough Therapy Designation For Pemvidutide, Balanced 1:1 Glucagon/GL

Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies t

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks
benzinga.com
Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune reports positive 48-week Phase 2b data for pemvidutide in MASH, showing fibrosis improveme

benzinga.com
Altimmune's Topline Results From IMPACT Phase 2b Trial Of Pemvidutide For Metabolic Dysfunction-Asso

Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo,

benzinga.com
Altimmune Announces Publication In The Lancet Of 24-Week Efficacy And Safety Data From Ongoing IMPAC

24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-f

benzinga.com
Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $14

Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and

benzinga.com
Altimmune Data From AI-Based Analysis Of Biopsies From IMPACT Phase 2b Trial Of Pemvidutide Demonstr

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel pept

benzinga.com
Altimmune Q3 EPS $(0.21) Beats $(0.27) Estimate, Sales $5.000K Beat $1.250K Estimate

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.21) per share which beat the analyst consens

Earnings Scheduled For November 6, 2025
benzinga.com
Earnings Scheduled For November 6, 2025

benzinga.com
Altimmune Completes Patient Enrollment In RECLAIM, Phase 2 Clinical Trial Evaluating Pemvidutide In

Enrollment completed ahead of schedule, underscoring strong interest from patient community in a pot

benzinga.com
HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy

benzinga.com
Altimmune To Present 24-Week Data From Phase 2b IMPACT Trial Of Pemvidutide In Metabolic Dysfunction

Oral presentation to highlight 24-week efficacy and safety dataPoster to feature results of AI-based

benzinga.com
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

benzinga.com
HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy

benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday
benzinga.com
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday

benzinga.com
What 5 Analyst Ratings Have To Say About Altimmune

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results
benzinga.com
These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

benzinga.com
Earnings Scheduled For August 12, 2025